Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome - Top-Institutions - MDSpire

Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome

  • By

  • Yassin A. Bashir

  • Ahmed A. Abdelrheem

  • Maymona Abdelmagid

  • Kaaren K. Reichard

  • Rong He

  • Cinthya J. Zepeda Mendoza

  • Animesh Pardanani

  • Naseema Gangat

  • Ayalew Tefferi

  • January 5, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Genomic Medicine

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Molecular Genetics

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Translational Research

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Hematology
    • Genomic Medicine
    • Clinical Research

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Genomics

Original Source(s)

Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome

  • by Yassin A. Bashir, Ahmed A. Abdelrheem, Maymona Abdelmagid, Kaaren K. Reichard, Rong He, Cinthya J. Zepeda Mendoza, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

  • January 5, 2026

Related Content

Multimodal management of late-stage Bockenheimer disease complicated by severe anemia and coagulopathy: a case report

Viable Gata2 deficient mice exhibit T cell development independent of adult definitive hematopoiesis

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases